MGH Center for Women's Mental Health https://validator.w3.org/feed/docs/rss2.html Welcome to the MGH Center for Women’s Mental Health Essential Reads: A Primer on Menopausal Hormone Therapy for Mental Health Providers Weekly Roundup for March 27, 2026: Recent Publications in Women’s Mental Health Beyond the EPDS: Using AI to Identify Women at Risk for Postpartum Depression Is There a Link Between Endometriosis and Perinatal Depression? Topiramate and Risk of Major Malformations: What Clinicians and Patients Need to Know Rapid Symptom Relief in Postpartum Psychosis with Brexanolone You Asked: What is Lithium Orotate? Can It Be Used During Pregnancy? Weekly Roundup for April 3, 2026: Recent Publications in Women’s Mental Health Collective Members Sleep Awareness Week: What You Should Know About Sleep and Perinatal Mental Health Beyond Hot Flashes: The Hidden Toll of Menopausal Sleep Disturbance on Well-Being The National Pregnancy Registry for ADHD Medications Introducing Members of The 2026 Psychiatry Collective National Pregnancy Registry for Atypical Antipsychotics National Pregnancy Registry for Psychiatric Medications © Bringing More Than Blue Documentary Across The Globe PMDD Treatment with Serotonin Reuptake Inhibitors: Neuroactive Steroids and GABA May Play a Role Can Esketamine Be Used to Prevent Postpartum Depression? Postpartum Depression with Comorbid Anxiety: Optimizing Treatment Don’t Forget About Brexanolone’s Little Sister: Zuranolone The National Pregnancy Registry for Sedative-Hypnotics and Other Sleep Medications Development of Zuranolone (SAGE 217) for PPD Will Move Forward More Data on the Neuroactive Steroid Zuranolone for Postpartum Depression National Pregnancy Registry for Antidepressants Essential Reads: Zuranolone for Postpartum Depression Improved Mental Health Outcomes Associated with Doula Support: A Review of the Evidence NPR’s 1A Live Discusses Perinatal Depression and the New Medication Zuranolone Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application for Zuranolone to the FDA in 2022 Zuranolone for Postpartum Depression: Results from the SKYLARK Study Zuranolone: Novel, Rapid-Acting Antidepressant Awaits FDA Approval Zuranolone Improves Anxiety Symptoms and Insomnia in Women with Postpartum Depression More Data on Zuranolone for Postpartum Depression: When Will It Hit the Market? FDA Approves Zuranolone for the Treatment of Postpartum Depression Zuranolone: A novel postpartum depression treatment, with lingering questions New Oral Drug Zuranolone (Zurzuvae) for Postpartum Depression is Now Available Your Patient Has Postpartum Depression: Do You Use Zuranolone or a Traditional Antidepressant? Telehealth Group Prenatal Care: Expanding Access and Connection to Pregnant Patients The Complex Motives Behind Cannabis Use During Pregnancy Intervention Implementation for Hot Flashes and Depression in Black Women Weekly Roundup for March 6, 2026: Recent Publications in Women’s Mental Health Weekly Roundup for February 20, 2026: Recent Publications in Women’s Mental Health On-Demand Courses (For Providers) Educational Program On-Demand Courses Educational Program OLD Announcing our 2026 Inaugural NP Masterclass Cohort Weekly Roundup for March 13, 2026: Recent Publications in Women’s Mental Health For Women with Bipolar Disorder: Sleep Disruption May Increase Risk of Postpartum Psychosis For International Women’s Day, Take Action to Improve Maternal Mental Health